Reference
Medicines and Healthcare products Regulatory Agency (UK). Cladribine (Mavenclad): new advice to minimise risk of serious liver injury. Internet Document : 15 Mar 2022. Available from: URL: https://www.gov.uk/drug-safety-update/cladribine-mavenclad-new-advice-to-minimise-risk-of-serious-liver-injury
Rights and permissions
About this article
Cite this article
MHRA issues new advice to monitor for liver injury from cladribine treatment. Reactions Weekly 1899, 2 (2022). https://doi.org/10.1007/s40278-022-11976-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-11976-y